Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Plans FY2022 Discussion over Linking National Health Database with Mortality Data
February 28, 2022
- Japan Pledges US$300 Million Contribution for CEPI
February 28, 2022
- Japan Cabinet OKs Draft Economic Security Bill
February 28, 2022
- Fertility Treatment Indications for 9 Meds to Be Reported to PAFSC Panel on March 9
February 25, 2022
- Therapeutic App for Hypertension Up for PAFSC Review on March 9
February 24, 2022
- Bill to Amend PMD Law Set for Cabinet Approval as Early as March 1
February 24, 2022
- Xevudy Delivery for 80,000 People Begins Ahead of Schedule: Health Minister
February 24, 2022
- No Reasonable Link between COVID-19 Vaccinations and Excess Deaths: MHLW Panels
February 22, 2022
- PMDA Reviewing New Safety Risks for Brilinta, Stocrin, Ofev
February 21, 2022
- All Company-Led Post-Marketing Studies Should Be Regulated by PMD Law upon Clinical Research Law Amendment: Panel
February 21, 2022
- Japan Weighs Pre-Approval Purchase of Shionogi’s COVID-19 Pill
February 21, 2022
- AZ’s Asthma Drug, Takeda HAE Med, Novartis CML Therapy and More Up for PAFSC Review on March 3
February 18, 2022
- Komeito Hears Update on Mitsubishi Tanabe’s COVID-19 Vaccine
February 18, 2022
- LDP Health Committee OKs Bill to Amend PMD Law
February 18, 2022
- Key Resource Suppliers to Be Fined for False Reporting: Draft Economic Security Bill
February 17, 2022
- MHLW Flags Xevudy Supply Disruption, Calls for Use of Other COVID-19 Drugs
February 17, 2022
- MHLW Calls for Considering Veklury Use as Tight Supply Expected for Xevudy
February 16, 2022
- Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
- Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too
February 16, 2022
- Japan Snags 10 Million Extra Doses of Pfizer Vaccine
February 15, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…